Por favor, use este identificador para citar o enlazar este ítem:
https://hdl.handle.net/10495/38003| Título : | Multicentric and Observational Study of Omalizumab for Chronic Spontaneous Urticaria in Real-Life in Colombia |
| Autor : | Sánchez Caraballo, Jorge Mario García Gómez, Elizabeth Chapman, Edgardo García Paba, María Beatriz Ocampo Gómez, Jaime Egea Bermejo, Eduardo Garavito De Egea, Gloria Fang, Luis Sarrazola, Mauricio Serrano Reyes, Carlos Silva Espinosa, Diana Lucia Rojas Mejía, Dolly Vanessa Moreno López, Sergio Mauricio |
| metadata.dc.subject.*: | Urticaria Angioedema Antagonistas de los Receptores Histamínicos Histamine Antagonists Omalizumab Antihistamínicos Antihistamines https://id.nlm.nih.gov/mesh/D014581 https://id.nlm.nih.gov/mesh/D000799 https://id.nlm.nih.gov/mesh/D006633 https://id.nlm.nih.gov/mesh/D000069444 |
| Fecha de publicación : | 2022 |
| Editorial : | Frontiers Media |
| Citación : | García-Gómez E, Chapman E, García-Paba MB, Ocampo-Gómez J, Egea-Bermejo E, Garavito-De Egea G, Fang L, Sarrazola M, Sánchez-Caraballo JM, Serrano-Reyes C, Silva-Espinosa DL, Rojas-Mejía DV, Moreno SM. Multicentric and Observational Study of Omalizumab for Chronic Spontaneous Urticaria in Real-Life in Colombia. Front Allergy. 2022 May 20;3:902344. doi: 10.3389/falgy.2022.902344. PMID: 35769574; PMCID: PMC9234875. |
| Resumen : | ABSTRACT: Although chronic urticaria (CU) is a common, cause of medical consulting both in general practitioners and allergist specialists worldwide, there is little information about its behavior and management in Latin America. Currently, national and international guidelines recommend using Omalizumab for cases refractory to management with antihistamines. Despite advances in the knowledge of Omalizumab for the management of CU, although there are few studies in underdeveloped countries, there are many studies evaluating the impact of Omalizumab treatment. There is not clinical information related with CSU-Omalizumab in patient settled in the Caribbean area. This research aims to evaluate the management of CU with Omalizumab in a real-life scenario in Colombia. |
| metadata.dc.identifier.eissn: | 2673-6101 |
| ISSN : | 2673-6101 |
| metadata.dc.identifier.doi: | 10.3389/falgy.2022.902344 |
| Aparece en las colecciones: | Artículos de Revista en Ciencias Médicas |
Ficheros en este ítem:
| Fichero | Descripción | Tamaño | Formato | |
|---|---|---|---|---|
| SanchezJorge_2022_OmalizumabInducibleAntihistamines.pdf | Artículo de investigación | 453.32 kB | Adobe PDF | Visualizar/Abrir |
Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons
